Archivserver der Deutschen Nationalbibliothek

65. Heublein B RR, Barlach S, Sternberg K, Schmitz K-P, Harder C, Bayer G,
Tittelbach M, Diener T, Hartwig S. Stents as carriers for applying a local
active agent: the concept of the "drug-eluting-stent. Progress in Biomed
Res. 2002; 5:216-225.
66. Regar E, Sianos G, Serruys PW. Stent development and local drug
delivery. Br Med Bull. 2001; 59:227-48.
67. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits
cell cycle regulators of proliferation in vascular smooth muscle cells.
Circ Res. 1995; 76:412-7.
68. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL. Different inhibitory
effects of immunosuppressive drugs on human and rat aortic smooth
muscle and endothelial cell proliferation stimulated by platelet-derived
growth factor or endothelial cell growth factor. J Heart Lung Transplant.
1997; 16:484-92.
69. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR.
Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest.
1996; 98:2277-83.
70. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S,
Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of
intimal thickening after balloon angioplasty in porcine coronary arteries
by targeting regulators of the cell cycle. Circulation. 1999; 99:2164-70.
71. Nuhrenberg TG, Voisard R, Fahlisch F, Rudelius M, Braun J, Gschwend
J, Kountides M, Herter T, Baur R, Hombach V, Baeuerle PA, Zohlnhofer
D. Rapamycin attenuates vascular wall inflammation and progenitor cell
promoters after angioplasty. Faseb J. 2005; 19:246-8.
72. Sousa JE CM, Abizaid AC. Sustained suppression of neointimal
proliferation by sirolimus-eluting stents: one-year angiographic and
intravascular ultrasound follow-up. Circulation. 2001; 104:2007-2011.
68